SG11201810396QA - Pegylated carfilzomib compounds - Google Patents

Pegylated carfilzomib compounds

Info

Publication number
SG11201810396QA
SG11201810396QA SG11201810396QA SG11201810396QA SG11201810396QA SG 11201810396Q A SG11201810396Q A SG 11201810396QA SG 11201810396Q A SG11201810396Q A SG 11201810396QA SG 11201810396Q A SG11201810396Q A SG 11201810396QA SG 11201810396Q A SG11201810396Q A SG 11201810396QA
Authority
SG
Singapore
Prior art keywords
california
international
pct
compounds
amgen
Prior art date
Application number
SG11201810396QA
Inventor
Gary Luehr
Shabbir T Anik
Ge Peng
Irina DOTSENKO
Pasit Phiasivongsa
Dante ROMANINI
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59062074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201810396Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201810396QA publication Critical patent/SG11201810396QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111 0111010101111111111111111111111111111111111111111111111111111111111111# International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/205392 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, C07D 405/12 (2006.01) A61K 47/10 (2017.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, C08G 65/331 (2006.01) C07K 5/10 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, A61P 35/00 (2006.01) C07K 5/117 (2006.01) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, A61K 38/07 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) PCT/US2017/034029 Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 23 May 2017 (23.05.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/340,926 24 May 2016 (24.05.2016) US 62/485,812 14 April 2017 (14.04.2017) US Declarations under Rule 4.17: (71) Applicant: AMGEN INC. [US/US]; One Amgen Center — Dr., Thousand Oaks, California 91320 (US). as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(0 Published: (72) Inventors: LUEHR, Gary; 28570 Fox Hollow Drive, Hay- — ward, California 94542 (US). ANIK, Shabbir T.; 1740 with international search report (Art. 21(3)) Broadway, Apt. 704, San Francisco, California 94109 (US). = PENG, Ge; 1002 Solana Drive, Mountain View, California 94040 (US). DOTSENKO, Irina; 1337 Sunny Court Apt 3, = _ San Jose, California 95116 (US). PHIASIVONGSA, Pa- - = sit; 2712 Saint Regis Avenue, Brentwood, California 94513 = (US). ROMANINI, Dante; 5921 Tobias Avenue, Sherman Oaks, California 91411 (US). = = (74) Agent: REDDY, Prabhakar, G. et al.; One Amgen Center Dr., Thousand Oaks, California 91320 (US). Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = Title: PEGYLATED CARFILZOMIB COMPOUNDS = (54) = = = PEG I= 0 ,.,.. ,-, M 0, In 0 H C ) ii (R ) \"*.!'\"N N N 0 r.;.N .--- ir 0.,) 0 0 p h 0 , Ph in 0 ei IN Formula I 1-1 (57) : The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts 0 N thereof, of Formula I wherein R 1 , R 2 , linker, PEG, n and o are as defined herein. The invention also provides methods of making and P1 using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.
SG11201810396QA 2016-05-24 2017-05-23 Pegylated carfilzomib compounds SG11201810396QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340926P 2016-05-24 2016-05-24
US201762485812P 2017-04-14 2017-04-14
PCT/US2017/034029 WO2017205392A1 (en) 2016-05-24 2017-05-23 Pegylated carfilzomib compounds

Publications (1)

Publication Number Publication Date
SG11201810396QA true SG11201810396QA (en) 2018-12-28

Family

ID=59062074

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912278TA SG10201912278TA (en) 2016-05-24 2017-05-23 Pegylated carfilzomib compounds
SG11201810396QA SG11201810396QA (en) 2016-05-24 2017-05-23 Pegylated carfilzomib compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912278TA SG10201912278TA (en) 2016-05-24 2017-05-23 Pegylated carfilzomib compounds

Country Status (24)

Country Link
US (3) US10517954B2 (en)
EP (1) EP3464277B1 (en)
JP (1) JP7142578B2 (en)
KR (1) KR102492135B1 (en)
CN (1) CN109415353B (en)
AU (1) AU2017272101B2 (en)
CA (1) CA3025170A1 (en)
CL (1) CL2018003352A1 (en)
CO (1) CO2018013112A2 (en)
CR (1) CR20180602A (en)
ES (1) ES2939849T3 (en)
IL (1) IL263147B (en)
MA (1) MA45148A (en)
MX (1) MX2018014498A (en)
NZ (1) NZ748615A (en)
PE (1) PE20190328A1 (en)
PH (1) PH12018502473A1 (en)
SG (2) SG10201912278TA (en)
TN (1) TN2018000393A1 (en)
TW (1) TWI759301B (en)
UA (1) UA125254C2 (en)
UY (1) UY37253A (en)
WO (1) WO2017205392A1 (en)
ZA (1) ZA201807890B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (en) 2016-05-24 2022-04-01 美商安美基公司 Pegylated carfilzomib compounds
MX2020004936A (en) * 2017-11-16 2020-08-27 Amgen Inc Stable compositions of pegylated carfilzomib compounds.
US20220370628A9 (en) * 2018-04-13 2022-11-24 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
WO2020254602A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
CN113979895B (en) * 2020-07-08 2023-03-24 中国科学技术大学 Self-degradable polymer with controllable precise sequence and preparation method and application thereof
CN115873231A (en) * 2022-12-17 2023-03-31 华南理工大学 Polyethylene glycol modified aminoglycoside molecule and preparation method and application thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0575545B1 (en) * 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US20040100225A1 (en) 2002-11-20 2004-05-27 Neil Robert Miles Cooling and control system for battery charging
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
JP4990155B2 (en) 2004-12-07 2012-08-01 プロテオリックス， インコーポレイテッド Composition for inhibiting proteasome
JP5073315B2 (en) 2006-03-24 2012-11-14 関西ペイント株式会社 Can coating composition
CL2008002966A1 (en) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Crystalline keto epoxide tetrapeptide compound; crystalline citrate salt of the compound; methods of preparation; crystalline intermediate compound; Preparation method; and use to treat cancer, autoimmune disease, transplant-related condition, neurodegenerative disease, condition associated with fibrosis, among others.
WO2009152160A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EA035100B1 (en) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Combination therapy with peptide epoxyketones
ES2647361T3 (en) 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Prodrugs of quaternary ammonium salts
WO2013169282A1 (en) 2012-05-08 2013-11-14 Onyx Therapeutics, Inc. Cylodextrin complexation methods for formulating peptide proteasome inhibitors
UY34897A (en) 2012-07-09 2014-01-31 Onyx Therapeutics Inc PROFESSIONALS OF PEPTIDIC INHIBITORS OF EXPOXI CETONA PROTEASA
CA2879139C (en) 2012-07-18 2021-05-11 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
DE102013104003B3 (en) 2013-04-19 2014-03-13 Glatt Systemtechnik Gmbh Device for introducing a defined amount of a second powder into a process container
WO2016004221A1 (en) 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
CN104530413B (en) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 A kind of bio-related substance of multiple functionalized H types polyethyleneglycol derivative modification
CN106310289B (en) 2015-06-24 2020-10-13 天津键凯科技有限公司 Conjugate of polyethylene glycol and anesthetic and preparation method thereof
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
ES2643856B1 (en) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles for the regulation of intracellular calcium homeostasis
TWI759301B (en) 2016-05-24 2022-04-01 美商安美基公司 Pegylated carfilzomib compounds
MX2018014455A (en) 2016-05-24 2019-01-24 Basf Se Herbicidal uracilpyrid.
BR112018072034A2 (en) 2016-05-24 2019-02-12 Novo Nordisk A/S mic-1 compounds and uses thereof
MX2018014443A (en) 2016-05-25 2019-04-15 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides.
MA45493A (en) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh HCMC ENTRY INHIBITORS.
JP6631420B2 (en) 2016-06-28 2020-01-15 株式会社デンソー Optical sensor
WO2018003319A1 (en) 2016-06-30 2018-01-04 パナソニックＩｐマネジメント株式会社 Operation method for laundry device, and program thereof
JP6512183B2 (en) 2016-06-30 2019-05-15 株式会社Ｓｏｋｅｎ Occupant detection system and occupant detection apparatus
JP6851640B2 (en) 2016-06-30 2021-03-31 Ｆｓテクニカル株式会社 Specimens, anchor test equipment and anchor test methods

Also Published As

Publication number Publication date
JP7142578B2 (en) 2022-09-27
CN109415353A (en) 2019-03-01
UA125254C2 (en) 2022-02-09
MX2018014498A (en) 2019-04-01
BR112018074078A2 (en) 2019-06-04
KR20190010648A (en) 2019-01-30
AU2017272101A1 (en) 2018-12-13
CA3025170A1 (en) 2017-11-30
TWI759301B (en) 2022-04-01
TN2018000393A1 (en) 2020-06-15
MA45148A (en) 2019-04-10
WO2017205392A1 (en) 2017-11-30
CN109415353B (en) 2023-01-10
UY37253A (en) 2017-11-30
EP3464277B1 (en) 2022-12-28
US10675353B2 (en) 2020-06-09
PH12018502473A1 (en) 2019-04-08
US20200069808A1 (en) 2020-03-05
ES2939849T3 (en) 2023-04-27
CO2018013112A2 (en) 2018-12-28
CL2018003352A1 (en) 2019-02-15
EP3464277A1 (en) 2019-04-10
US10517954B2 (en) 2019-12-31
ZA201807890B (en) 2019-08-28
CR20180602A (en) 2019-03-04
IL263147A (en) 2018-12-31
KR102492135B1 (en) 2023-01-26
US20200376131A1 (en) 2020-12-03
US20170340746A1 (en) 2017-11-30
US11077198B2 (en) 2021-08-03
TW201808345A (en) 2018-03-16
NZ748615A (en) 2022-11-25
SG10201912278TA (en) 2020-02-27
JP2019519530A (en) 2019-07-11
IL263147B (en) 2022-04-01
AU2017272101B2 (en) 2021-10-07
PE20190328A1 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
SG11201810396QA (en) Pegylated carfilzomib compounds
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201807912SA (en) Vaccine against rsv
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201808125RA (en) Methods for solid tumor treatment
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201909837YA (en) Methods for treating lung disorders
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders